Targeted immunotherapy Emerging NK and innate T cell based therapies position Sandhill as a potential partner for large biopharma with immuno-oncology portfolios seeking novel, cost-effective cellular approaches.

Strategic collaborations With a focused product platform and early-stage revenue, there is an opportunity to pursue co-development or licensing discussions with big pharma players seeking to augment existing pipelines with universal cellular therapies.

Low headcount, high leverage Small team size suggests lean operations; potential buyers can offer strategic partnerships, manufacturing scale-up, or technology integration support without requiring heavy integration work on Sandhill's side.

Cloud and data readiness Active use of AWS, Firebase, and modern web technologies indicates readiness for secure collaboration platforms, data sharing, and joint clinical data management systems with potential enterprise customers.

Financial signals Revenue under one million highlights a founders-led, pre-revenue phase with ample room for investment through partnerships, milestone-based funding, or contract research collaborations to accelerate development.